Enanta Pharmaceuticals, Inc. (ENTA)
12.50
+0.40
(+3.31%)
USD |
NASDAQ |
Oct 09, 16:00
12.48
-0.02
(-0.12%)
After-Hours: 20:00
Enanta Pharmaceuticals Free Cash Flow : -36.94M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -36.94M |
| March 31, 2026 | -9.609M |
| December 31, 2025 | -18.46M |
| September 30, 2025 | -32.17M |
| June 30, 2025 | -43.57M |
| March 31, 2025 | -82.24M |
| December 31, 2024 | -96.48M |
| September 30, 2024 | -96.71M |
| June 30, 2024 | -100.33M |
| March 31, 2024 | -113.29M |
| December 31, 2023 | -99.19M |
| September 30, 2023 | -112.21M |
| June 30, 2023 | -106.21M |
| March 31, 2023 | -101.79M |
| December 31, 2022 | -112.07M |
| September 30, 2022 | -86.91M |
| June 30, 2022 | -90.99M |
| March 31, 2022 | -91.04M |
| December 31, 2021 | -69.30M |
| September 30, 2021 | -70.75M |
| June 30, 2021 | -65.48M |
| March 31, 2021 | -40.34M |
| December 31, 2020 | -21.31M |
| September 30, 2020 | 5.643M |
| June 30, 2020 | 29.68M |
| Date | Value |
|---|---|
| March 31, 2020 | 34.75M |
| December 31, 2019 | 48.01M |
| September 30, 2019 | 66.00M |
| June 30, 2019 | 85.47M |
| March 31, 2019 | 88.11M |
| December 31, 2018 | 52.20M |
| September 30, 2018 | 26.24M |
| June 30, 2018 | 55.59M |
| March 31, 2018 | 47.11M |
| December 31, 2017 | 51.86M |
| September 30, 2017 | 50.15M |
| June 30, 2017 | -9.466M |
| March 31, 2017 | -6.654M |
| December 31, 2016 | 5.467M |
| September 30, 2016 | 31.07M |
| June 30, 2016 | 29.66M |
| March 31, 2016 | 17.78M |
| December 31, 2015 | 108.00M |
| September 30, 2015 | 74.34M |
| June 30, 2015 | 72.88M |
| March 31, 2015 | 122.21M |
| December 31, 2014 | 19.18M |
| September 30, 2014 | 19.15M |
| June 30, 2014 | 21.86M |
| March 31, 2014 | -18.84M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Perspective Therapeutics, Inc. | -121.38M |
| Coherus Oncology, Inc. | -186.03M |
| BridgeBio Pharma, Inc. | -437.79M |
| RenovoRx, Inc. | -11.94M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -9.972M |
| Cash from Investing (Quarterly) | 14.00M |
| Cash from Financing (Quarterly) | -5.542M |
| Free Cash Flow Per Share (Quarterly) | -0.343 |
| Free Cash Flow to Equity (Quarterly) | -5.402M |
| Free Cash Flow to Firm (Quarterly) | -5.841M |
| Free Cash Flow Yield | -10.92% |